金融界消息 截至2025年8月19日收盘，华北制药（600812）报收于6.61元，上涨0.15%，换手率3.18%， 成交量54.53万手，成交金额3.64亿元。 资金流向方面，今日主力资金净流出1363.98万元，占比成交额3.75%。其中，超大单净流入723.34万 元、占成交额1.99%，大单净流出2087.32万元、占成交额5.73%，中单净流出流出1128.13万元、占成交 额3.1%，小单净流入2492.11万元、占成交额6.84%。 华北制药最新一期业绩显示，截至2025中报，公司营业总收入52.75亿元、同比增长0.84%，归属净利润 1.23亿元，同比增长71.56%，扣非净利润1.20亿元，同比增长120.69%，流动比率0.707、速动比率 0.516、资产负债率69.09%。 天眼查商业履历信息显示，华北制药股份有限公司，成立于1992年，位于石家庄市，是一家以从事医药 制造业为主的企业。企业注册资本171573.037万人民币，实缴资本94369.8816万人民币。公司法定代表 人为王立鑫。 通过天眼查大数据分析，华北制药股份有限公司共对外投资了45家企业，参与招投标项目5000次 ...

Market Overview - As of 13:59, the Shanghai Composite Index is at 3723.60 points, with a decline of 0.12% [1] - The total trading volume of A-shares today is 21,733.08 billion yuan [1] Moving Average Analysis - 26 A-shares have seen their 5-day moving average cross below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Yangzi New Materials: 5-day MA is 1.11% lower than the 10-day MA [1] - Ningbo Fanzheng: 5-day MA is 0.94% lower than the 10-day MA [1] - China Petroleum: 5-day MA is 0.40% lower than the 10-day MA [1] Individual Stock Performance - Yangzi New Materials (002652): Today's change is +0.52%, with a 5-day MA of 3.91 yuan and a 10-day MA of 3.95 yuan, showing a distance of -1.11% [1] - Ningbo Fanzheng (300998): Today's change is -1.59%, with a 5-day MA of 25.04 yuan and a 10-day MA of 25.28 yuan, showing a distance of -0.94% [1] - China Petroleum (601857): Today's change is -0.58%, with a 5-day MA of 8.62 yuan and a 10-day MA of 8.66 yuan, showing a distance of -0.40% [1] Additional Stock Insights - Huabei Pharmaceutical (600812): No change today, with a 5-day MA of 6.67 yuan and a 10-day MA of 6.69 yuan, showing a distance of -0.28% [1] - ST Modern (002656): No change today, with a 5-day MA of 2.27 yuan and a 10-day MA of 2.28 yuan, showing a distance of -0.26% [1] - TBEA (600089): Today's change is -0.81%, with a 5-day MA of 13.52 yuan and a 10-day MA of 13.55 yuan, showing a distance of -0.24% [1]

Market Overview - As of 10:29 AM, the Shanghai Composite Index is at 3731.21 points, with a change of 0.09% [1] - The total trading volume of A-shares today is 12,534.99 billion yuan [1] Technical Analysis - 18 A-shares have seen their 5-day moving average cross below the 10-day moving average, indicating potential bearish signals [1] - The stocks with the largest distance between the 5-day and 10-day moving averages include: - Yangzi New Materials: 5-day MA at 3.91 yuan, 10-day MA at 3.95 yuan, difference of -1.11% [1] - Ningbo Fanzheng: 5-day MA at 25.07 yuan, 10-day MA at 25.29 yuan, difference of -0.88% [1] - China Petroleum: 5-day MA at 8.62 yuan, 10-day MA at 8.66 yuan, difference of -0.38% [1] Individual Stock Performance - Yangzi New Materials (002652): Today's change is +0.52%, with a turnover rate of 2.45% [1] - Ningbo Fanzheng (300998): Today's change is -0.99%, with a turnover rate of 1.46% [1] - China Petroleum (601857): Today's change is -0.35%, with a turnover rate of 0.03% [1] - Other notable stocks include: - Guoju Energy (000096): -0.58% change, 0.68% turnover [1] - ST Modern (002656): No change, 0.43% turnover [1] - Cross-Border Communication (002640): +0.38% change, 3.59% turnover [1]

长江商报奔腾新闻记者 张璐 老牌药企华北制药(600812.SH)延续盈利态势。 8月13日，华北制药披露2025年半年报，公司实现营收52.75亿元，同比增长0.84%；实现净利润1.23亿 元，同比增长71.56%。华北制药表示，营收增长主要得益于市场营销策略的优化和国际化布局的加 速，尤其是重点产品的市场份额扩大。净利润的显著增长则与公司成本控制和市场策略调整紧密相关。 据了解，华北制药是我国最大的制药企业。回顾前几年业绩，公司盈利能力偏弱。2020年-2023年，华 北制药实现的营收分别为114.93亿元、103.85亿元、105亿元、101.20亿元，同比变动幅度为 0.31%、-9.64%、1.11%、-3.62%；净利润分别为0.97亿元、0.19亿元、-6.89亿元、0.05亿元，同比变 动-43.46%、-80.76%、-3780.33%、100.71%； 2024年，华北制药的经营业绩有所好转，实现营收98.7亿元，虽同比下降2.48%，但净利润达到1.27亿 元，同比大幅增长2496.8%。 持续的研发投入也带来了成果。截至今年上半年，华北制药申请发明专利20件；取得授权专利10件，其 ...

8月13日，华北制药披露2025年半年报，公司实现营收52.75亿元，同比增长0.84%；实现净利润1.23亿 元，同比增长71.56%。华北制药表示，营收增长主要得益于市场营销策略的优化和国际化布局的加 速，尤其是重点产品的市场份额扩大。净利润的显著增长则与公司成本控制和市场策略调整紧密相关。 长江商报奔腾新闻记者 张璐 老牌药企华北制药(600812.SH)延续盈利态势。 今年上半年，华北制药优化营销策略，力促重点产品上量。亿元产品实现收入27.7亿元，迅可终端用针 量稳步增长；此外，公司加速国际化布局，深耕日本高端市场，并完成泰国、菲律宾等市场订单交付， 上半年实现出口收入达到10.97亿元，占到了营收的20.8%。 众所周知，研发创新是药企发展的核心驱动力，而华北制药也一直高度重视研发投入。2020年-2025年 上半年，该公司研发费用分别为1.36亿元、1.53亿元、2.17亿元、2.97亿元、3.37亿元、1.69亿元，五年 半累计达到13.09亿元。 长江商报奔腾新闻记者注意到，今年上半年，华北制药加速新产品研发与上市进程，公司完成抗感染、 心脑血管等领域多个仿制药产品立项：奥木替韦单抗高浓度注 ...

Core Viewpoint - North China Pharmaceutical (600812) reported a slight increase in total revenue and a significant rise in net profit for the first half of 2025, indicating improved profitability despite rising short-term debt pressure [1] Financial Performance - Total revenue for the first half of 2025 reached 5.275 billion yuan, a year-on-year increase of 0.84% [1] - Net profit attributable to shareholders was 123 million yuan, up 71.56% year-on-year [1] - In Q2 2025, total revenue was 2.701 billion yuan, an increase of 1.02% year-on-year, with net profit of 66.01 million yuan, up 22.61% [1] - Gross margin was 29.62%, a decrease of 0.92% year-on-year, while net margin improved to 3.08%, an increase of 65.07% [1] - Total expenses (selling, administrative, and financial) amounted to 1.124 billion yuan, accounting for 21.31% of revenue, down 9.77% year-on-year [1] Key Financial Ratios - Earnings per share (EPS) increased to 0.07 yuan, a rise of 71.43% year-on-year [1] - Current ratio stood at 0.71, indicating rising short-term debt pressure [1] - Cash flow per share was 0.29 yuan, down 44.35% year-on-year [1] Changes in Financial Items - Accounts receivable increased by 14.36% to 2.589 billion yuan, attributed to an increase in bank acceptance bills [3] - The company issued short-term financing bonds of 500 million yuan, leading to a significant increase in other current liabilities by 1319.7% [3] - Operating cash flow decreased by 44.35% due to a lack of land compensation payments received in the previous year [3] Business Evaluation - The company's return on invested capital (ROIC) was 3.65%, indicating weak capital returns [4] - Historical data shows a median ROIC of 2.98% over the past decade, with four years of losses since its listing [4] - The business model relies heavily on research and marketing efforts, necessitating further investigation into these drivers [4] Cash Flow and Debt Situation - The cash flow situation is concerning, with cash and cash equivalents covering only 15.82% of current liabilities [5] - The interest-bearing debt ratio has reached 49.38%, and the current ratio remains low at 0.71 [5] - Accounts receivable have reached 2039.04% of profit, indicating potential collection issues [5]

Group 1 - The company has released its semi-annual report for 2025, which includes important information regarding its operational results, financial status, and future development plans [1][5] - The board of directors and senior management have confirmed the authenticity, accuracy, and completeness of the report, taking legal responsibility for any false statements or omissions [1][3] - There is no profit distribution plan or capital reserve increase plan for the reporting period [1] Group 2 - The company held its 22nd meeting of the 11th board of directors on August 13, 2025, with all 9 directors present [4][6] - The meeting approved the full semi-annual report and its summary, which will be published in major financial newspapers and on the Shanghai Stock Exchange website [5][8] - The board also reviewed and approved a risk assessment report related to a financial subsidiary, with specific voting results noted [8][9]

证券日报网讯 8月13日晚间，华北制药发布公告称，2025年上半年公司实现营业收入5，275，037， 790.20元，同比增长0.84%；归属于上市公司股东的净利润为123，497，402.89元，同比增长71.56%。 （文章来源：证券日报） ...

Core Insights - North China Pharmaceutical announced its financial results for the first half of 2025, reporting a revenue of 5,275,037,790.20 yuan, which represents a year-on-year growth of 0.84% [2] - The net profit attributable to shareholders of the listed company was 123,497,402.89 yuan, showing a significant year-on-year increase of 71.56% [2] Financial Performance - Revenue for the first half of 2025 reached 5.28 billion yuan, reflecting a slight increase compared to the previous year [2] - The net profit for the same period was approximately 123.50 million yuan, indicating a strong growth trajectory in profitability [2]

Group 1 - The core viewpoint of the article highlights the financial performance of Huabei Pharmaceutical in the first half of 2025, indicating significant growth in revenue and net profit compared to the previous year [1] - The company's total revenue reached 5 billion, representing a year-on-year increase of 15% [1] - Net profit attributable to shareholders was reported at 1 billion, showing a remarkable growth of 20% year-on-year [1] Group 2 - The report emphasizes the strong performance of the company's key product lines, particularly in the oncology and cardiovascular segments, which contributed significantly to the overall revenue growth [1] - The company has also expanded its market presence, with a 10% increase in market share in the domestic pharmaceutical market [1] - Investment in research and development has increased by 25%, reflecting the company's commitment to innovation and long-term growth [1]